SAB Biotherapeutics, Inc. (SABS) Financials
SABS Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-09-30 | 28.3 million | 13.1 million |
| 2023-06-30 | 35.4 million | 15.7 million |
| 2023-03-31 | 50.9 million | 19.8 million |
| 2022-12-31 | 50.9 million | 19.8 million |
SABS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-09-30 | -5.3 million | 639246 |
| 2023-06-30 | -4.9 million | 644815 |
| 2023-03-31 | 18.5 million | 269018 |
| 2022-12-31 | 18.5 million | 269018 |
SABS Net Income
No data available :(
SABS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-09-30 | 2.4 million | - | 4.1 million |
| 2023-06-30 | 7.8 million | 541644 | 4.3 million |
| 2023-03-31 | 15.0 million | - | 4.5 million |
| 2022-12-31 | - | - | 4.6 million |
SABS Shares Outstanding
SABS Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-09-30 | 85306 | 4.0 million | 2.6 million | - |
| 2023-06-30 | 22684 | 3.7 million | 2.9 million | - |
| 2023-03-31 | 8.9 million | 7.1 million | 2.9 million | - |
| 2022-12-31 | 117754 | 7.1 million | 2.9 million | - |
SABS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-09-30 | 1.3 million | 985446 |
| 2023-06-30 | 85518 | 892266 |
| 2023-03-31 | 2.2 million | 923524 |
| 2022-12-31 | - | - |
SABS
Price: $4.03
52 week price:
Earnings Per Share: -7.64 USD
P/E Ratio: -0.99
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 35000
Market Capitalization: 41.5 million